A 52-year-old man with major depressive disorder and chronic neuropathic pain from diabetic peripheral neuropathy presents for antidepressant initiation. He has no cardiac contraindications. Which antidepressant is most appropriate as first-line therapy given his comorbid pain condition?
A. Fluoxetine
B. Mirtazapine
C. Venlafaxine
D. Bupropion
Explanation
Antidepressant Selection in Depression with Comorbid Chronic Pain
Key Point
When major depressive disorder coexists with chronic pain syndromes (neuropathic pain, fibromyalgia, chronic musculoskeletal pain), serotonin–norepinephrine reuptake inhibitors (SNRIs) are preferred over SSRIs because they target both monoamine systems implicated in pain modulation.
SNRIs: Mechanism and Pain Efficacy
Mnemonic
SNRIs = Dual action — both serotonin AND norepinephrine reuptake inhibition.
Table
SNRI
Dose (mg/day)
Serotonin Inhibition
Norepinephrine Inhibition
Pain Indication
Venlafaxine
75–225
✓ Strong
✓ Strong (dose-dependent)
Neuropathic pain, fibromyalgia
Duloxetine
60–120
✓ Strong
✓ Strong
Neuropathic pain, fibromyalgia, chronic pain
Desvenlafaxine
50–100
✓ Strong
✓ Strong
Neuropathic pain
High-YieldNEET PG
Venlafaxine and duloxetine have the strongest evidence base for efficacy in neuropathic pain and are FDA/WHO-approved for this indication.
Clinical Pearl
Tip
In this patient—depression + diabetic neuropathic pain—venlafaxine is an excellent choice because:
1.
It treats both the mood disorder and the pain syndrome with a single agent.
It reduces the need for polypharmacy and improves adherence.
Why Other Options Are Suboptimal
Fluoxetine (SSRI): Effective for depression but minimal efficacy for neuropathic pain. Lacks norepinergic activity needed for pain modulation. Would require concurrent pain medication (e.g., gabapentin, pregabalin, tricyclic).
Bupropion (NDRI): Unique mechanism (norepinephrine–dopamine reuptake inhibition); activating but poor efficacy for pain syndromes. Contraindicated in seizure disorders; not indicated for neuropathic pain.
Mirtazapine (Tetracyclic): Sedating; useful in depression with insomnia but minimal evidence for neuropathic pain efficacy. Alpha-2 antagonism may worsen some pain conditions.
Evidence Summary
SNRIs (venlafaxine, duloxetine) have Level A evidence for efficacy in:
Diabetic peripheral neuropathic pain
Fibromyalgia
Chronic musculoskeletal pain
Postherpetic neuralgia
Harrison 21e Ch 470; Uptodate Neuropathic Pain Management
Practice similar questions
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.
